Kimberly‑Clark Updates on Kenvue Deal (KMB)

Kimberly‑Clark has provided explicit mechanics for the Kenvue acquisition: each Kenvue share will receive 0.14625 KMB shares plus $3.50 in cash. Management expects to issue roughly 280 million new KMB shares as part of the transaction structure. Stockholder approval was completed in January 2026, and the company continues to target a closing in the second half of 2026. Regulatory approvals remain a gating factor. The company has reiterated the standard transaction risks: regulatory uncertainty, potential conditions that could delay or alter the deal, and the possibility of termination or renegotiation if material approvals are not obtained. The recent procedural steps (including a two‑step merger and related debt exchange offer announced on 2026‑09‑28) are part of the execution path toward closing but do not eliminate regulatory or antitrust risk.

Management disclosed the expected issuance of ~280 million new shares to effect the share portion of consideration, creating clear dilution pressure for existing holders. Kimberly‑Clark’s balance sheet at December 31, 2025 shows cash of $634 million and total debt of $7,247 million (Debt/EBITDA ~2.7x). The company also entered new credit facilities in December 2025 (a five‑year revolving facility and a delayed draw term loan) that form part of its financing toolkit. Near‑term capital needs include expected 2026 capital spending of roughly $1.3 billion and completion costs for the 2024 Transformation Initiative. Management signaled that share repurchases will be subject to acquisition financing needs, and the combination of new equity issuance plus existing debt maturities highlights financing and dilution as material execution risks tied to closing Kenvue.

Kimberly‑Clark frames the Kenvue acquisition as part of a broader portfolio transformation alongside the IFP joint venture. The 2024 Transformation Initiative targets $3.0 billion in gross productivity savings and ~$200 million in SG&A savings, with total pre‑tax program costs of ~$1.5 billion and expected completion by end‑2026. Cumulative pre‑tax charges through 2025 were ~$1.1 billion. Key operational risks called out by management include integration execution, input cost volatility (cellulose and pulp), birth‑rate declines that pressure diapers and baby care volume, and geopolitical/currency headwinds. The company also noted legacy legal and regulatory exposures (including a DOJ‑related matter tied to its former health care business that reached a settlement in Q2 2025 but carries residual risk). Finally, the IFP transaction leaves Kimberly‑Clark with a 49% non‑controlling interest, which limits operational control over that business.